Overview

Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection

Status:
Unknown status

Trial end date:
2014-11-01

Target enrollment:
0

Participant gender:
All

Summary

This study will be conducted on 30 patients with mucocutaneous complaints and documented HCV infection. The study will be done at Tropical medicine department , Tanta university. It will be conducted between June2014 and November 2014. The aim of the study is to assess efficacy of Ribavirin in the management of mucocutaneous extrahepatic manifestations of HCV infection.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Tanta University

Treatments:

Antimetabolites
Antiviral Agents
Betamethasone
Betamethasone benzoate
Betamethasone sodium phosphate
Betamethasone Valerate
Betamethasone-17,21-dipropionate
Ribavirin

Criteria

Inclusion Criteria:

- Patients with evidence of HCV infection and mucocutaneous complaint and
contraindicated to have standard antiviral therapy.

Exclusion Criteria:

- Hypersensitivity to Ribavirin

- Pregnant & Lactating women

- Male partners of pregnant women